Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment

• Hauptverfasser: Yingying Zhang (Verfasst von), Hongxia Duan (Verfasst von), Heming Zhao (Verfasst von), Lingling Qi (Verfasst von), Yanhong Liu (Verfasst von), Zheao Zhang (Verfasst von), Chao Liu (Verfasst von), Liqing Chen (Verfasst von), Mingji Jin (Verfasst von), Youyan Guan (Verfasst von), Zhonggao Gao (Verfasst von), Wei Huang (Verfasst von)
• Format: Buch
• Veröffentlicht: MDPI AG, 2022-04-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Primary prostate cancer (PC) progresses to castration-resistant PC (CRPC) during androgen deprivation therapy (ADR) in early stages of prostate cancer. Thus, rather than blocking the androgen-related pathway further, docetaxel (DTX)-based therapy has become the most effective and standard first-line...